US-based biopharmaceutical company Ignyta (Nasdaq: RXDX) says it has received offers for a potential sub-licensing deal, or sale, related to oncology candidate taladegib.
Ignyta, which acquired the franchise from Eli Lilly (NYSE: LLY) in 2015, has revised the terms of its agreement with the pharma major to permit such a deal.
Taladegib is a small molecule antagonist that has achieved clinical proof-of-concept and a recommended Phase II dose based on results from prior clinical studies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze